The groundbreaking success of Sildenafil undeniably transformed the drug landscape, but investing in companies strongly reliant on generic versions presents a uncertain picture. Although early earnings were substantial, the cessation of patents and the emergence of discounted alternatives have weakened the customer base. Thus, a thorough analysis o